清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Abstract 2417: Detection and quantification of site-specific DNA methylation from liquid biopsies as a pharmacodynamic biomarker of OTX-2002, a novel MYC-targeting epigenomic mRNA therapeutic

表观遗传学 生物标志物 DNA甲基化 药效学 甲基化 计算生物学 液体活检 生物 癌症研究 DNA CpG站点 分子生物学 癌症 基因 药理学 遗传学 基因表达 药代动力学
作者
Justin Chen,William Senapedis,Stephen K. Siecinski,Elmer Figueroa,Adam J. Katz,Samuel Mildrum,Yaoyu E. Wang,Houda Belaghzal,Kayleigh Gallagher,Graeme Hodgson,Colm P. O’Donnell,Thomas McCauley
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (6_Supplement): 2417-2417
标识
DOI:10.1158/1538-7445.am2024-2417
摘要

Abstract Omega Therapeutics has developed a novel platform of programmable epigenomic mRNA medicines capable of modifying chromatin state to specifically tune gene expression at the pre-transcriptional level. Epigenomic controllers (ECs) unlock targets that have been historically considered “undruggable,” with one of the most elusive being the MYC oncogene. A direct MYC-targeting anti-cancer agent has previously remained intangible, largely due to the absence of a drug binding pocket and tight autoregulation. A clinical trial is underway (MYCHELANGELO, NCT05497453) to investigate pre-transcriptional inhibition of MYC with OTX-2002 in patients with hepatocellular carcinoma (HCC). OTX-2002, a first-in-class mRNA therapeutic delivered via lipid nanoparticles (LNP), encodes two proteins that durably modify chromatin, in part, through CpG DNA methylation at the MYC locus. Using both liquid and solid biopsy sampling from in vivo studies, we investigated whether target engagement for OTX-2002 could be assessed by MYC methylation. Detection of DNA methylation has long held promise as an oncology biomarker given its functional roles in various cancer types and the potential signal afforded by methylated CpGs. Indeed, DNA methylation has been shown to serve as a robust analyte in liquid biopsy-derived multi-cancer early detection (MCED) and minimal residual disease (MRD) tests that have recently been utilized in the clinic. Many of these platforms are founded on complex models that leverage methylation signals across >1 million CpGs that can span tens of megabases of genomic space. We faced a distinct challenge when compared to these MCED/MRD tests in developing a pharmacodynamic methylation assay for OTX-2002 as the target region consists of just a few kilobases. With a tissue specific LNP delivery system, ultra-high sensitivity was required to identify rare ctDNA events from the larger cfDNA population. To this end, we designed a minimal hybridization/capture panel that targeted ~50 kb of genomic space, effectively allowing for ultra-deep methylation sequencing of MYC. When this technique was paired with enzymatic (EM) conversion for methylation detection and supported by an analysis pipeline focused on epiallele identification, this assay was able to detect methylation down to the theoretical limit in a dilution series of control genomic DNA, 1 in 104 copies of MYC. This degree of sensitivity translated to successful preclinical detection of on-target methylation by OTX-2002 from DNA extracted from plasma samples collected from mice-bearing human HCC xenografts. Overall, we present a non-invasive and exquisitely sensitive method of assessing target engagement and site-specific pharmacodynamic activity of a novel epigenomic medicine that can be directly translated to the clinical setting. Citation Format: Justin Chen, William Senapedis, Stephen Siecinski, Elmer Figueroa, Adam Katz, Samuel Mildrum, Yaoyu E. Wang, Houda Belaghzal, Kayleigh Gallagher, Graeme Hodgson, Charles W. O'Donnell, Thomas G. McCauley. Detection and quantification of site-specific DNA methylation from liquid biopsies as a pharmacodynamic biomarker of OTX-2002, a novel MYC-targeting epigenomic mRNA therapeutic [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2417.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
单薄涵梅完成签到,获得积分10
11秒前
老戎完成签到 ,获得积分10
20秒前
爱笑的笑旋完成签到,获得积分10
29秒前
爆米花的应助被科研通管家采纳,获得10
33秒前
nnn关闭了nnn的文献求助
34秒前
科研民工完成签到,获得积分10
37秒前
Zyou完成签到,获得积分10
55秒前
落后的雨筠完成签到,获得积分10
58秒前
1分钟前
大意的之柔完成签到,获得积分10
1分钟前
依然灬聆听完成签到,获得积分10
1分钟前
会发光的小叶子完成签到,获得积分10
1分钟前
漂亮傲云完成签到,获得积分10
1分钟前
勤劳寒松完成签到,获得积分10
1分钟前
风趣馒头完成签到,获得积分10
1分钟前
激动的发卡完成签到,获得积分10
2分钟前
李健的应助被科研通管家采纳,获得10
2分钟前
Maestro_S的应助被科研通管家采纳,获得10
2分钟前
null的应助被科研通管家采纳,获得10
2分钟前
时尚的青易完成签到,获得积分10
2分钟前
感性的鸡完成签到,获得积分10
2分钟前
嘻嘻完成签到,获得积分10
3分钟前
英俊的青烟完成签到,获得积分10
3分钟前
marine完成签到 ,获得积分10
3分钟前
3分钟前
向连虎发布了新的文献求助10
3分钟前
3分钟前
超级诗桃完成签到,获得积分10
4分钟前
绛仙旧友完成签到,获得积分10
4分钟前
无辜的水蜜桃完成签到,获得积分10
4分钟前
liunahan完成签到 ,获得积分10
4分钟前
JUN完成签到,获得积分10
4分钟前
4分钟前
瞿人雄完成签到,获得积分10
4分钟前
没心没肺完成签到,获得积分10
4分钟前
4分钟前
向连虎发布了新的文献求助10
4分钟前
null的应助被科研通管家采纳,获得10
4分钟前
王哇噻完成签到 ,获得积分10
4分钟前
阳光幻巧完成签到,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166338
求助须知:如何正确求助?哪些是违规求助? 9559484
关于积分的说明 21750435
捐赠科研通 7757131
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553469
邀请新用户注册赠送积分活动 2473812